Answers are grounded in this paper and cite their sources.
Pretreatment AMH is a useful predictor of long term post chemotherapy loss of ovarian function in women with eBC, adding significantly to the only previously established individualising predictor, i.e. age. AMH measurement may assist decision-making regarding treatment options and fertility preservation procedures.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: